iShares Nasdaq Biotechnology Index Fund ETF News

Sector ETF report for IBB

Yahoo Finance's Jared Blikre joins the Live show to break down how stocks are trading as Fed Chair Powell continues to testify before Congress.

The fund covers the same market as an existing Syntax ETF, but invests mainly in individual stocks rather than other ETFs.

Biotech stocks have had a terrible year so far. Patent expirations will force biopharma giants to look towards smaller companies.

Biotechnology sector stocks seem to be in the oversold zone, as indicated by their momentum and valuations. I compared XBI (small-cap biotech ETF) and IBB (all-cap biotech ETF) to select the most prom

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech

Jared Holz, Oppenheimer healthcare equity strategist, on biotech stocks to watch. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Bonawyn Eison.

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader

Mish's Economic Modern Family looks to have found temporary support as each of the members has closed over the prior day's high providing relief from the downward trend. However, will this last, or is

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Smart Beta ETF report for IBB

Biotech stocks had enjoyed strong hype and trajectories in the recent past, especially during the pandemic years. This is beginning to unravel. ETFs covering this sector have a massive preponderance o

Sector ETF report for IBB

After suffering one of their worst Aprils in years, biotech sector-related exchange traded funds could be in for even more pain ahead. Year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI) has declin

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages.